Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. - Suppr | 超能文献

Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.

作者信息

Hotta Katsuyuki, Inoue Akira, Kiura Katsuyuki, Ueoka Hiroshi, Nukiwa Toshihiro, Tanimoto Mitsune

出版信息

Lung Cancer. 2005 Dec;50(3):413-5. doi: 10.1016/j.lungcan.2005.07.006. Epub 2005 Sep 8.

DOI:10.1016/j.lungcan.2005.07.006

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.

Lung Cancer. 2005 Dec;50(3):413-5. doi: 10.1016/j.lungcan.2005.07.006. Epub 2005 Sep 8.

2

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.单药吉非替尼治疗未经治疗的晚期非小细胞肺癌且体能状态较差患者：明妮·珀尔癌症研究网络II期试验

Clin Lung Cancer. 2005 Sep;7(2):127-32. doi: 10.3816/CLC.2005.n.028.

3

[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].吉非替尼治疗49例晚期非小细胞癌的疗效分析

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):635-6.

4

Acute gefitinib-induced pneumonitis.急性吉非替尼诱发的肺炎。

Int J Clin Oncol. 2004 Oct;9(5):406-9. doi: 10.1007/s10147-004-0418-0.

5

APL during gefitinib treatment for non-small-cell lung cancer.吉非替尼治疗非小细胞肺癌期间出现的急性早幼粒细胞白血病（APL）

N Engl J Med. 2005 Feb 24;352(8):843. doi: 10.1056/NEJM200502243520825.

6

Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.

Chin Med J (Engl). 2006 Jan 5;119(1):63-8.

7

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.在一项扩大准入研究中接受吉非替尼（ZD1839，“易瑞沙”）治疗的晚期非小细胞肺癌患者的治疗结果。

Lung Cancer. 2004 May;44(2):221-30. doi: 10.1016/j.lungcan.2003.12.014.

8

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.在接受吉非替尼治疗既往治疗过的晚期或转移性非小细胞肺癌患者中，皮疹和支气管肺泡组织学与临床获益相关。

Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14.

9

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.吉非替尼对非小细胞肺癌脑转移患者有效，且疗效与皮肤毒性相关。

Lung Cancer. 2005 Jan;47(1):129-38. doi: 10.1016/j.lungcan.2004.05.014.

10

Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.新型化疗药物的副作用和良好效果。病例1.吉非替尼诱导的间质性纤维化。

J Clin Oncol. 2005 Apr 1;23(10):2423-4. doi: 10.1200/JCO.2005.04.055.

引用本文的文献

1

Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit.对重症监护病房中初治肺癌患者进行癌症治疗的结果。

J Cancer. 2017 Jul 5;8(11):1995-2003. doi: 10.7150/jca.18178. eCollection 2017.

2

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂用于老年或体能状态差的晚期非小细胞肺癌患者

Target Oncol. 2009 Jan;4(1):37-44. doi: 10.1007/s11523-009-0104-2. Epub 2009 Jan 20.